Opioids are
directed to the patients suffering from the acute and chronic non-cancer pain.
The opioids have numerous adverse intestinal effects, such as opioid-induced
constipation. The opioids also affect the discharge of digestive enzymes that
can sometime cause partial gastro paresis. Some of the most familiar symptoms
of opioid-induced constipation includes, hard and dry stools, swelling, painful
defecation, distention and protruded abdomen, tiredness, and loss of hunger.
Some of the most common opioid-induced constipation therapy is the use of
targeted therapies, OTC and off-label drugs and changing lifestyle.
On the
basis of different form of drug the global opioid-induced constipation market
can be bifurcated into two broad categories: solid and liquid. Some of the
dominant market drivers for opioid-induced constipation includes, rising number
of OIC patients, and widespread use of opioids treatment in chronic non-cancer
pain. The current opioid-induced constipation market is led by the inexpensive
and widely available laxatives. The clinical efficiency of laxatives is poor
compared to its counterparts; however they still broadly used in constipation
relief.
Lack of
awareness about the opioid-induced constipation in patients, and the doctors
are one of the dominant causes of off-label and OIC medications as majorly used
treatment methods. However, the efficiency of these drugs is only the half of
some of the other therapies. The entrance of superficially acting mu-opioid
receptor rivals such as Movantikv or Moventig are driving the opioid-induced
constipation market. Movantikv or Moventig drug targets only the fundamental
reason of opioid-induced constipation without affecting the effect of the
opioid drugs.
Request to Get the
Sample Pages at:
Europe was
the largest market of the opioid-induced constipation market in 2015 in terms
of value. It is then followed by North America. The market dominance of Europe
is attributed the presence of a large number of baby boomers population in the
region. North America was the fastest growing market for opioid-induced
constipation in 2014, the market size of North America is expected to surpass
the Europe during the forecast period. The high growth of the market is
attributed to the supportive government incentive in healthcare services in
addition with the presence of a large pool of patients suffering from chronic
pain.
Make Enquiry Before
Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=opioid-induced-constipation-market
In
September 2014 the U.S. Food and Drug Administration (FDA) has approved methyl
naltrexone bromide hypodermic injection, 12 mg/0.6ml, for the treatment of
opioid-induced constipation for the patients using opioids non-cancer chronic
pain. This approval from the FDA is expected to serve approx. 11 million
patients in the U.S. who are suffering from opioid-induced constipation.
Based on
the different form of therapy the global opioid-induced constipation market can
be broadly categorized as non-tamper resistant formulations (non-TRFs) and
tamper resistant formulations (TRF). The non-TRFs has the largest market share
in 2014, however the TRFs is expected to more dominant treatment technology in
upcoming years attributed mainly to the U.S. Food and Drug Administration (FDA)
promotions and broad pipeline of oral
(TRFs) approval.
Some of the
major players operating in the global
opioid-induced constipation market include, AstraZeneca plc, Valeant
Pharmaceuticals International Inc., Takeda Pharmaceutical Co. Ltd., Salix
Pharmaceuticals, Ltd., Progenics Pharmaceuticals, Inc., Abbott Laborites, and
Bayer AG among others.
